A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

May 28, 2012

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions
Solid Tumors Harboring a BRAF V600 Mutation
Interventions
DRUG

LGX818

DRUG

MEK162

DRUG

LEE011

Trial Locations (26)

2060

Melanoma Institute Australia, North Sydney

2065

Melanoma Institute Australia, North Sydney

2145

Westmead Hospital-Redbank Rd, Westmead

Westmead Hospital, Westmead

2152

Westmead Hospital-Redbank Rd, Northmead

3000

UZ Leuven- Gasthuisberg Campus, Leuven

8058

University Hospital Zürich, Dermatology, Zurich-Airport

9007

Kantonsspital St. Gallen, Sankt Gallen

20162

ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda, Milan

21287

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

28050

Hospital Universitario HM Sanchinarro ? CIOCC, Madrid

33612

H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa

Moffitt McKinley Outpatient Center, Tampa

75010

Hôpital Saint louis, Paris

75475

Service de radiologie - Hopital Saint Louis, Paris

77030

The University of Texas MD Anderson Cancer Center, Houston

80131

IRCCS Fondazione Pascale, Naples

Azienda Ospedaliera Monaldi, Napoli

Azienda Ospedaliera Universitaria Federico II, Napoli

Istituto Nazionale per lo studio e la cura dei tumori Fondazione Giovanni Pascale, Napoli

169610

National Cancer Centre Singapore, Singapore

02114

Massachusetts General Hospital, Boston

Ophthalmic Consultants of Boston Inc (OCB), Boston

02050

Chris O'Brien Lifehouse Hospital, Camperdown

H3T 1E2

Sir Mortimer B. Davis-Jewish General Hospital, Montreal

08035

Hospital Universitario Vall d'Hebrón - PPDS, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY